Commercial BioAgilytix snaps MicroConstants to further build contract research services

BioAgilytix snaps MicroConstants to further build contract research services


A global bioanalytical laboratory, BioAgilytix Labs LLC, specialized in large molecule bioanalysis and drug development, snapped up a deal to acquire MicroConstants, a GLP-compliant Contract Research Organization (CRO), to expand its family of pharmaceutical and biotech companies.   

MicroConstants Inc., a U.S. based bioanalytical laboratory, with headquarters  located in San Diego, California, is going to be named as BioAgilytix San Diego.

The company focuses on providing services like validation, method development or sample analysis for developing novel small and large molecule therapeutics and biomarkers with the help of immunoassay (including multiplexing and high sensitivity SIMOA), HPLC, LC/MS/MS and qPCR techniques. The company has supported over 290 other pharmaceutical and biotech companies since 1998.

“We are excited to welcome the MicroConstants team to BioAgilytix and to work with them to integrate the business… We believe that by joining forces, BioAgilytix and MicroConstants will not only create significant scientific and performance synergies, but also we are better able to serve the growing biotechnology community on the West Coast. Most importantly, our customers and their patients will benefit from the leading-edge science the combined company will bring to market,” President and CEO of BioAgilytix Labs, Jim Datin, stated.

The U.S. based company has served its clients throughout the pharma and biotech industry for more than 20 years by performing GLP-compliant bioanalytical services. MicroConstants’ business will add to the contract research services of BioAgilytix’s for the industry. However, MicroConstants China will not become part of the deal and will continue its operations as a separate business entity.

+ posts

Latest news

Revvity introduces advanced preclinical imaging tech for scientists to make breakthroughs

Revvity, Inc. is ushering in a new era of innovation in the realm of preclinical research by...

European Commission Approves Updated Pfizer-BioNTech Vaccine for Omicron XBB.1.5 Variant

The European Commission has recently achieved a significant milestone in the ongoing battle against COVID-19 in preparation...

NICE gives Chiesi’s Elfabrio go ahead

Chiesi has recently garnered a favorable recommendation from the National Institute for Health and Care Excellence (NICE)...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you